Physician profile
Lori A Fields
NPI 1629063763
$2,180.95
in general payments reported to CMS, 2019-2025
19 companies · $19.36 in 2025
The $19.36 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,210 · 2022: $935 · 2023: $16.80 · 2025: $19.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $36.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $36.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $487.88 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $312.21 | 2021-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.78 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $179.86 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $166.99 | 2021-2022 | |
| Csl Behring | $142.74 | 2021-2022 | |
| Optinose US, INC. | $85.00 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $71.96 | 2021 | |
| Grifols USA, LLC | $71.08 | 2022 | |
| Pfizer INC. | $69.34 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.47 | 2021-2022 | |
| Genzyme Corporation | $62.39 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $42.46 | 2021 | |
| Kaleo, INC. | $37.08 | 2022 | |
| Octapharma USA, INC. | $28.06 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $24.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.83 | 2022 | |
| Novo Nordisk INC | $19.36 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.